Intensive_chemotherapy_induction_followed_by_interferon-alpha_maintenance_in_patients_with_Philadelphia_chromosome-positive_chronic_myelogenous_leukemia._In_a_pilot_study,_32_patients_with_Philadelphia_chromosome-positive_chronic_myelogenous_leukemia_were_treated_with_intensive_chemotherapy_induction_followed_by_interferon-alpha_(IFN-A)_maintenance._Intensive_chemotherapy_consisted_of_three_cycles_of_daunorubicin_120_mg/m2_on_day_1,_cytarabine_80_mg/m2_daily_for_10_days,_vincristine_2_mg_on_day_1,_and_prednisone_100_mg_daily_for_5_days_(DOAP)._Maintenance_therapy_with_IFN-A_at_a_doses_of_3_x_10(6)_to_5_x_10(6)_units/m2_daily_was_adjusted_according_to_counts_and_toxicity._The_outcome_of_patients_was_compared_with_a_matched_historic_population_of_64_patients_treated_with_IFN-A_alone._Overall,_60%_of_patients_had_a_cytogenetic_response_(partial_or_complete)_with_induction_chemotherapy,_but_only_eight_(25%)_had_a_sustained_cytogenetic_response_with_IFN-A_maintenance._After_a_median_follow-up_of_67_months,_the_6-year_survival_rate_of_the_32_patients_was_58%,_compared_with_36%_for_the_matched_historic_group_(P_=_0.084)._The_incidence_of_lymphoid_blastic_transformation_in_the_two_groups_was_25%_and_48%,_respectively_(P_=_0.10)_and_durable_cytogenetic_responses,_25%_and_19%,_respectively_(P_=_0.48)._In_summary,_the_addition_of_intensive_chemotherapy_induction_to_IFN-A_maintenance_does_not_improve_the_survival_rate,_incidence_of_lymphoid_blastic_transformation,_or_incidence_of_durable_cytogenetic_response_compared_with_the_results_achieved_with_IFN-A_therapy_alone.